140 related articles for article (PubMed ID: 38662366)
1. Comparison of programmed death-ligand 1 expression in adenocarcinoma and squamous cell carcinoma of the cervix in paraffin blocks of patients with cervical cancer.
Hosseini MS; Shafizadeh F; Bahremani MH; Farzaneh F; Ashrafganjoei T; Arab M; Talayeh M; Jafari F; Abdshah A
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2057. PubMed ID: 38662366
[TBL] [Abstract][Full Text] [Related]
2. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.
Heeren AM; Punt S; Bleeker MC; Gaarenstroom KN; van der Velden J; Kenter GG; de Gruijl TD; Jordanova ES
Mod Pathol; 2016 Jul; 29(7):753-63. PubMed ID: 27056074
[TBL] [Abstract][Full Text] [Related]
3. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.
Yang W; Lu YP; Yang YZ; Kang JR; Jin YD; Wang HW
J Obstet Gynaecol Res; 2017 Oct; 43(10):1602-1612. PubMed ID: 28833798
[TBL] [Abstract][Full Text] [Related]
4. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas.
Reddy OL; Shintaku PI; Moatamed NA
Diagn Pathol; 2017 Jun; 12(1):45. PubMed ID: 28623908
[TBL] [Abstract][Full Text] [Related]
5. Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients.
Omenai SA; Ajani MA; Okolo CA
PLoS One; 2022; 17(2):e0263615. PubMed ID: 35139126
[TBL] [Abstract][Full Text] [Related]
6. Programmed death-ligand 1 (PD-L1) expression in cervical intraepithelial neoplasia and cervical squamous cell carcinoma of HIV-infected and non-infected patients.
Brito MJ; Sequeira P; Quintas A; Silva I; Silva F; Martins C; Félix A
Virchows Arch; 2024 Mar; 484(3):507-516. PubMed ID: 37341812
[TBL] [Abstract][Full Text] [Related]
7. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers.
Mezache L; Paniccia B; Nyinawabera A; Nuovo GJ
Mod Pathol; 2015 Dec; 28(12):1594-602. PubMed ID: 26403783
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
[TBL] [Abstract][Full Text] [Related]
9. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
Matsubara T; Takada K; Azuma K; Takamori S; Toyokawa G; Haro A; Osoegawa A; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
Ann Surg Oncol; 2019 Jun; 26(6):1925-1933. PubMed ID: 30815803
[TBL] [Abstract][Full Text] [Related]
10. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer.
Enwere EK; Kornaga EN; Dean M; Koulis TA; Phan T; Kalantarian M; Köbel M; Ghatage P; Magliocco AM; Lees-Miller SP; Doll CM
Mod Pathol; 2017 Apr; 30(4):577-586. PubMed ID: 28059093
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy.
Chinn Z; Stoler MH; Mills AM
Histopathology; 2019 Jan; 74(2):256-268. PubMed ID: 30067880
[TBL] [Abstract][Full Text] [Related]
12. Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.
Dibbern ME; Bullock TN; Jenkins TM; Duska LR; Stoler MH; Mills AM
Am J Surg Pathol; 2020 Sep; 44(9):1184-1191. PubMed ID: 32496434
[TBL] [Abstract][Full Text] [Related]
13. Identifying Rational Candidates for Immunotherapy Targeting PD-1/PD-L1 in Cervical Cancer.
Kim M; Kim H; Suh DH; Kim K; Kim H; Kim YB; No JH
Anticancer Res; 2017 Sep; 37(9):5087-5094. PubMed ID: 28870938
[TBL] [Abstract][Full Text] [Related]
14. The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix.
Karpathiou G; Chauleur C; Mobarki M; Peoc'h M
Pathol Res Pract; 2020 Jan; 216(1):152782. PubMed ID: 31862202
[TBL] [Abstract][Full Text] [Related]
15. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
16. Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix.
Zong L; Zhang Q; Zhou Y; Kong Y; Yu S; Chen J; Zhang Y; Xiang Y
J Immunol Res; 2020; 2020():1283632. PubMed ID: 32322590
[TBL] [Abstract][Full Text] [Related]
17. Programmed death-ligand 1 expression in human papillomavirus-independent cervical adenocarcinoma and its prognostic significance.
Chen L; Lucas E; Zhang X; Liu Q; Zhuang Y; Lin W; Chen H; Zhou F
Histopathology; 2022 Jan; 80(2):338-347. PubMed ID: 34455625
[TBL] [Abstract][Full Text] [Related]
18. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
